Monthly Archives: February 2021

//February

Supply Disruption Alert: Morphine Sulphate granules for oral suspension (MST Continus)

Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for Morphine Sulphate prolonged release granules for oral suspension (MST Continus) . Alert reference: SDA/2021/04 All strengths of MST Continus® prolonged release granules for oral suspension are being permanently discontinued during 2021 due to difficulty sourcing a key excipient. .  ...

By |February 26th, 2021|Lexpos News|Comments Off on Supply Disruption Alert: Morphine Sulphate granules for oral suspension (MST Continus)

February 2021 Price Concessions Final Update

The Department of Health and Social Care (DHSC) has today granted the following list of price concessions: Drug  Pack Size Price Concession Duloxetine 20mg gastro-resistant capsules 28 £7.28 Eplerenone 50mg tablets 28 £31.32 Etoricoxib 60mg tablets 28 £3.25 Etoricoxib 90mg tablets 28 £4.10 Lamotrigine 200mg tablets 56 £7.13 Letrozole 2.5mg tablets 14 £2.45 Sulfasalazine 500mg...

By |February 26th, 2021|Lexpos News|Comments Off on February 2021 Price Concessions Final Update

Contact centre closed today 12:00 – 14:00

Our contact centre will be closed today between 12:00 - 14:00 due to staff training.

By |February 26th, 2021|Lexpos News|Comments Off on Contact centre closed today 12:00 – 14:00

Contractor Notice: Further extension to SSP08

The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Salazopyrin® EN-Tabs 500mg (SSP08). SSP08 for Salazopyrin® EN-Tabs 500mg was previously expected to expire on 22nd January 2021 but the end date has been further extended to 8th March 2021. Please note: expiry dates of an...

By |February 26th, 2021|Lexpos News|Comments Off on Contractor Notice: Further extension to SSP08

Reporting COVID-19 lateral flow test results – AI trial

NHS Digital is trialling new artificial intelligence (AI) software to read test results of lateral flow devices (LFDs), which will make reporting results quicker, easier to understand and more accurate. Primary care staff, including pharmacy team members, reporting their test results will be able to take part in this trial from the end of next...

By |February 25th, 2021|Lexpos News|Comments Off on Reporting COVID-19 lateral flow test results – AI trial